Korea Q3 Roundup: China Sales, Prescription Drugs, Vaccines Boost Results
GC Pharma, SK Bioscience Stand Out
Executive Summary
Notable third-quarter developments at major Korean pharma firms included the domestic reimbursement of Yuhan’s Leclaza, the approval of Hanmi’s Rolontis and SK Bioscience's approval filing for Novavax's COVID-19 vaccine for supply in the country, a roundup of results by Scrip shows.